Aktienanalyse zu Myomo Inc (MYO)MYOMyomo Inc

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Myomo Inc is a good buy right now due to its recent strong earnings report showing a 21% year-over-year revenue growth to $11.7 million and an impressive gross margin of 72.1%. The stock is currently priced at $1.20, significantly below the analyst's target price of $10.50, indicating substantial upside potential. Additionally, insider buying has surged by 1251.40% over the last month, suggesting strong confidence from those closest to the company. The main risk is the negative earnings per share (EPS) estimate of -0.08 for the upcoming quarter, indicating ongoing challenges in achieving profitability.

1 analysts cover MYO: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.75.